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I NTRO D U C TIO N
Retinopathy of prematurity (ROP) is a postnatal disorder of retinal vessels that develops in the incompletely vascularised retina of preterm infants. (1) Only preterm infants whose retinal vessels have not yet completed centrifugal growth from the optic disk to the ora serrata may develop ROP. (2) Although this disorder regresses in most patients, it can lead to severe visual impairment. ROP is a major cause of childhood blindness in both developing and developed countries, despite striking advances in neonatology. (3) ROP is associated with excessive oxygen use in preterm newborn infants. (4) It is a biphasic disease consisting of an initial phase of vessel loss followed by a second phase of vessel proliferation. (3) (4) (5) It is clear that a growth factor, or several growth factors, regulated by hypoxia and hyperoxia is important in the development of ROP. (5) Vasculogenesis and angiogenesis are the results of a complex interaction between locally and systemically produced growth factors or mitogenes that stimulate or inhibit differentiation, proliferation, migration and maturation of endothelial cells. (6) It is increasingly difficult to ignore the roles of vascular endothelial growth factor (VEGF) and insulin-like growth factor-1 (IGF-1) in ROP. Initially thought to be a tumour-derived permeability enhancing factor, VEGF was later shown to be an endothelial cell mitogen. (6, 7) Studies with animal models support the central role of VEGF in ocular neovascularisation. (8) (9) (10) Clinical ROP is multifactorial -other biochemical mediators are also involved in the pathogenesis of retinopathy. Growth hormone and IGF-1 have been suspected to play a role in retinal neovascularisation, such as through control of VEGF activation. (11) (12) (13) However, far too little attention has been paid to these markers in proliferative ROP. This study was performed to determine the levels of the biochemical mediators IGF-1 and VEGF in the blood of premature infants with proliferative ROP.
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R E SU lT S
We included 71 preterm newborn infants in this study, out of which 30 were diagnosed with proliferative ROP (i.e. the study group) and 41 had normal ophthalmologic examinations (i.e. the control group). The demographic characteristics of the infants in the two groups are shown in Table I .
The study group's Apgar scores at 1 and 5 mins after birth were significantly lower than those in the control group (p < 0.001 and p = 0.001, respectively). Surfactant replacement therapy was done for 11 (26.8%) infants in the control group and 15 (50%) infants in the study group (p = 0.045). The two groups were significantly different with regard to the need for surfactant replacement therapy, duration of mechanical ventilation, and respiratory support requirements (Table II) Table III .
Diode laser photocoagulation was performed in 21 infants with threshold ROP. Mean IGF-1 levels in infants of different postmenstrual ages is showed in Table IV .
D I SCU S S IO N
ROP is an important cause of blindness in both developed and developing countries. (3) World Health Organization's (14) It has been long believed that oxygen therapy leads to an increased risk of ROP in preterm infants. (2) However, ROP can occur even with careful use of oxygen. (4) Several factors increase the risk of ROP, including low gestational age, low birth weight, sepsis, intraventricular haemorrhage, blood transfusion and mechanical ventilation. (15, 16) In our study, we found lower Apgar scores and severe respiratory distress (which manifested as a need for surfactant replacement therapy), longer assisted ventilation and use of continuous positive airway pressure to be significantly more common in infants who developed proliferative ROP. Our findings concur with the findings in a study by Karna et al. (15) With respect to the pathogenesis of ROP, inhibition of vascularisation in the early phase of ROP has been attributed to the hypoxic suppression of VEGF. A lack of IGF-1 in this phase of ROP may also prevent normal retinal vascular growth.
In phase II of ROP, pathologic vascular proliferation appears to be associated with rising levels of VEGF and IGF-1 induced by hypoxia. (3, 5, 17, 18) Several studies have also assessed IGF-1 and VEGF so as to define their role in the pathogenesis of ROP. (17) (18) (19) (20) (21) (22) (23) (24) (25) Different studies have yielded different results -this may be due to variations in study design, the wide range of gestational ages and postnatal ages of study groups, different sample sizes and different stages of ROP. A study by Pérez-Muñuzuri et al (17) showed reduced IGF-1 levels in infants who developed ROP (n = 3) three weeks postpartum, independent of gestational age at birth; a rapid rise in IGF-1 levels between the third and fifth weeks postpartum appeared to be related to progression to a higher stage of ROP. Only three patients with proliferative ROP were included in Pérez-Muñuzuri et al's study. (17) In another study, elevated VEGF and reduced IGF-1 levels were reported in infants with ROP, though the severity of ROP was specified. (18) Hellström et al (26) conducted a study measuring serum IGF-1 levels weekly and showed that low serum IGF-1 levels correlated with a later development of ROP. Hellström et al also concluded that the mean IGF-1 level at postmenstrual weeks 30 to 33 is a predictive factor of ROP that is as important as the degree of prematurity. (26) In our study, there was no statistically significant difference in IGF-1 and VEGF levels between preterm infants with proliferative ROP and those without at 6-8 weeks after birth.
This lack of significant difference in VEGF and IGF-1 levels in the present study could be due to the higher postnatal and postmenstrual ages of our cohort at sampling. IGF-1 level is known to be affected by gestational age, birth weight, protein intake and stage of retinopathy. (18) (19) (20) In our study, most of the infants in the study group were in the proliferative phase of ROP at sampling. In the more severe stages of ROP (at 6-8 weeks after birth), the blood levels of IGF-1 and VEGF reach levels not different from those in infants without ROP.
Our study has some limitations, such as the small cohort of infants. As there was a lack of serial measurement of biochemical markers, we could not show the variations in these parameters over time. However, an advantage of our study is that ophthalmologic examinations were performed consistently and all infants were seen by the same ophthalmologist for the entire duration of the study.
In conclusion, our data demonstrated that at 6-8 weeks after birth, the blood levels of IGF-1 and VEGF were not significantly different between premature infants with proliferative ROP and those without. *Data is presented as mean ± standard deviation. IGF-1: insulin-like growth factor-1
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